Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 3;11(1):3325.
doi: 10.1038/s41467-020-17140-5.

Cancer immunotherapy comes of age and looks for maturity

Amanda Finck  1 , Saar I Gill  1 , Carl H June  2   3
Affiliations
Review

Cancer immunotherapy comes of age and looks for maturity

Amanda Finck et al. Nat Commun. .

Abstract

As Nature Communications celebrates a 10-year anniversary, the field has witnessed the transition of cancer immunotherapy from a pipe dream to an established powerful cancer treatment modality. Here we discuss the opportunities and challenges for the future.

PubMed Disclaimer

Conflict of interest statement

C.H.J. is a scientific founder and has equity in Tmunity Therapeutics and is a consultant for Carisma Therapeutics, Celldex, Kiadis Pharma, Viracta and WIRB-Copernicus Group. S.I.G. is a scientific founder and has equity in Carisma Therapeutics. A.F. declares no competing interests.

Figures

Fig. 1
Fig. 1. Overview of new tools immunotherapeutic developments and multiplexed approaches to improve their efficacy.
a Immune checkpoint blockade can be augmented with oncolytic viruses and CAR T cells. b Oncolytic viruses can be engineered to secrete cytokines or combined with engineered T cells. c Advancements in protein engineering have allowed the development of trispecifics, orthogonal cytokine receptor pairs, which allow for selective stimulation of these engineered T cells. d Genome engineering has produced CAR-Ms and genome editing with CRISPR allow for multiple editing of multiple genes in T cells.
See this image and copyright information in PMC

References

    1. Tauriello DVF, et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538–543. doi: 10.1038/nature25492. - DOI - PubMed
    1. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 2007;15:651–659. doi: 10.1038/sj.mt.6300108. - DOI - PubMed
    1. Wang G, et al. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat. Commun. 2020;11:1395. doi: 10.1038/s41467-020-15229-5. - DOI - PMC - PubMed
    1. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 2015;14:642–662. doi: 10.1038/nrd4663. - DOI - PMC - PubMed
    1. Wu L, et al. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nat. Cancer. 2020;1:86–98. doi: 10.1038/s43018-019-0004-z. - DOI - PubMed

Publication types

MeSH terms